Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study (Q41740586)

8 October 2017

title

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study (English)

1 reference

8 October 2017

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Michele Maio

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Riccardo Danielli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Roberto Patuzzo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Gianfrancesco Gallino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Andrea Maurichi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Dario Neri

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Mario Santinami

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Anna Maria Di Giacomo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Annabella Di Florio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ornella Cutaia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Andrea Lazzeri

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Carolina Fazio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Clelia Miracco

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Leonardo Giovannoni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

14 May 2015

1 reference

Cancer Immunology, Immunotherapy

8 October 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

999-1009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

Local and intralesional therapy of in-transit melanoma metastases

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

High response rate after intratumoral treatment with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Immunocytokines: a novel class of potent armed antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Systemic use of tumor necrosis factor alpha as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Intra-lesional interleukin-2 therapy for in transit melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1704-6

10.1007/S00262-015-1704-6

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 June 2020

1048148850

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25971540%20AND%20SRC:MED&resulttype=core&format=json